ECO Animal Health receives marketing authorisation from MOA of the People’s Republic of China for the use of Aivlosin® WSG

ECO Animal Health Group plc (LON:EAH) has announced that its subsidiary ECO Animal Health Limited has received two marketing authorisations from the Ministry of Agriculture and Rural Affairs of the People’s Republic of China for the use of Aivlosin® Water Soluble Granules. Aivlosin® is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.

The first approval allows ECO to market Aivlosin® WSG in China for the treatment of respiratory disease caused by Mycoplasma and other sensitive bacteria in chickens laying eggs for human consumption and breeding chickens. Aivlosin® is the first antimicrobial to be licensed by the Chinese MOA for laying birds with a zero day drug withdrawal period for eggs.

The second Aivlosin® WSG approval is for swine respiratory disease adding three important bacterial respiratory pathogens of swine, Haemophilus parasuis, Pasteurella multocida, and Streptococcus suis to the existing Mycoplasma hyopneumoniae registration. SRD occurs worldwide and causes major economic losses to the pig industry due to mortality, reduction in growth rates and decreased feed efficiency.

Marc Loomes, ECO Animal Health CEO, commented: “We are delighted to receive these important marketing authorisations for Aivlosin® WSG. China is the world’s largest producer of table eggs and accounts for more than a third of the world’s laying birds. Aivlosin® is the first antimicrobial registered for use in laying hens producing eggs for human consumption, with a zero day egg withdrawal period.  This will enable ECO to target a new sector, the commercial egg producer, where Mycoplasmosis can cause significant economic losses.  China is also the largest pork producing country in the world and broader product label claims in the key SRD segment will serve our  business well as the market recovers in the future.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
ECO Animal Health Group plc

More articles like this

ECO Animal Health Group plc

Eco Animal Health delivering on earnings and R&D progress (VIDEO)

Eco Animal Health Group plc (LON:EAH) CEO David Hallas joins DirectorsTalk Interviews to discuss interim results for the six months ended 20th September. David talks us through the highlights, improved Chinese pork prices, excitement over new product developments, what

ECO Animal Health Group plc

ECO Animal Health Group appoint Haysmacintyre LLP as auditor

Following a competitive tender process overseen by the Group’s Audit & Risk Committee, ECO Animal Health Group (LON:EAH) has announced the resignation of BDO LLP as auditor and the appointment, with immediate effect, of Haysmacintyre LLP as auditor for the

ECO Animal Health Group plc

ECO Animal Health AGM to be held on 26 September 2022

ECO Animal Health Group plc (LON:EAH) has announced the publication of the following documents on the Company’s website: www.ecoanimalhealthgroupplc.com/investor-relations.aspx. ·     Annual Report and Accounts for the year ended 31 March 2022 ·    Notice of Annual General Meeting to be held

ECO Animal Health Group plc

ECO Animal Health delivers record China revenue in Q1

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has provided an update to its expected results for the year ended 31 March 2022.  The audit

ECO Animal Health Group plc

ECO Animal Health signs new bank facility agreement with NatWest

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that it has signed a new bank facility agreement with its bank, National Westminster Bank

ECO Animal Health Group plc

ECO Animal Health partners with Moredun Research Institute

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that its wholly owned subsidiary, ECO Animal Health Ltd, has entered into a research partnership

ECO Animal Health Group plc

ECO Animal Health Group pleased with recent trading

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets has provided an unaudited trading update for the financial year ending 31st March 2022. ECO commented in

ECO Animal Health Group plc

ECO Animal Health live investor presentation

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that Marc Loomes, CEO, Christopher Wilks, CFO, and Hafid Benchaoui, Global Head of R&D, will be

ECO Animal Health Group plc

ECO Animal Health appoint Tracey James as a Non-Executive Director

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health market, is pleased to announce the appointment of Tracey James as a Non-Executive Director with immediate effect. Tracey

No more posts to show